Multi-dimensional mycelia interactions

The activities of competing wood decay fungi bring about the decomposition of deadwood. The rate of decomposition is determined by the community composition, which is shaped by competitive interactions. Fungi compete with one another for territory and resources within 3 dimensional space via the production of an arsenal of inhibitory chemical compounds, yet interspecific interactions and chemical warfare within communities have never before been studied in 3 dimensional resources. This thesis, therefore, aims to determine how interactions cause metabolic processes to change, and, by the use of novel 3 dimensional systems, how those processes are affected by increased species diversity and spatial heterogeneity. Overarching hypotheses which have driven investigations are: (1) secondary metabolism and interaction outcome are inherently linked, both of which are affected by environmental conditions, (2) changes to spatial distributions and increased species diversity cause interaction outcomes and community dynamics to alter, and (3) changes to metabolic strategies for antagonism and resource utilisation will reflect alterations to community dynamics. Transitive interactions in pair wise 2 dimensional systems often became intransitive in species richer 3 dimensional systems, and the extent of patch fragmentation determined the length of coexistence of individuals within communities. Production of secondary metabolites comprising the fungal chemical weaponry, namely extracellular lignocellulolytic enzymes and volatile organic compounds (VOCs), was significantly different between 2 and 3 dimensional systems, between systems of varied species diversity, and between different spatial distributions of fungi, reflecting the observed changes to community dynamics. Furthermore, the production of intracellular metabolites which function in the biosynthesis pathways of antimicrobial compounds and agents of decay, was affected by species diversity, spatial distributions and territory fragmentation. Additionally, secondary metabolism and interaction outcome were found to be inherently linked, and affected by abiotic conditions. Specifically, interaction outcomes changed under different temperatures, and when wood was pre colonised for different lengths of time. Changes to the production of both enzymes and VOCs reflected the different outcomes, as either the cause or effect of outcome changes. These conclusions not only confirm the thesis hypotheses, but also demonstrate the importance of environmental conditions, species diversity and spatial dynamics to fungal community dynamics and forest ecosystem functioning

Emergent properties arising from spatial heterogeneity influence fungal community dynamics

Community dynamics are mediated by species interactions, and within communities spatial heterogeneity and intransitive relationships promote coexistence. However, few experimental studies have assessed effects of heterogeneity on the interactions of competing individuals. Wood decay basidiomycete fungi are ideal for studying community structure and dynamics because they are easy to manipulate in laboratory microcosms, and communities resolve themselves rapidly. Most studies have only used simplistic pair-wise interactions in a 2-D plane, but here we investigate a three-species community in an environmentally realistic novel 3-dimensional system. We show how spatial heterogeneity and patch size dynamics are important for coexistence, and how competitive interactions change over different spatial dimensions. Emergent properties arose with increased spatial heterogeneity: the weakest competitor co-occurred with the community when its territory was less fragmented, and interactions became intransitive

Space and patchiness affects diversity–function relationships in fungal decay communities

The space in which organisms live determines health and physicality, shaping the way in which they interact with their peers. Space, therefore, is critically important for species diversity and the function performed by individuals within mixed communities. The biotic and abiotic factors defined by the space that organisms occupy are ecologically significant and the difficulty in quantifying space-defined parameters within complex systems limits the study of ecological processes. Here, we overcome this problem using a tractable system whereby spatial heterogeneity in interacting fungal wood decay communities demonstrates that scale and patchiness of territory directly influence coexistence dynamics. Spatial arrangement in 2- and 3-dimensions resulted in measurable metabolic differences that provide evidence of a clear biological response to changing landscape architecture. This is of vital importance to microbial systems in all ecosystems globally, as our results demonstrate that community function is driven by the effects of spatial dynamics

The whiff of decay: Linking volatile production and extracellular enzymes to outcomes of fungal interactions at different temperatures

The terrestrial carbon cycle is largely driven by photosynthetic plants and decomposer organisms that process biomass to CO2. In forest ecosystems, the decomposers are predominantly wood decay fungi, and the response of community structure and activity to increasing global temperatures is likely critical to forest biogeochemical processes. Metabolic products can drive community structure and substrate utilisation, and the role of volatile organic compounds (VOCs), as well as extracellular enzymes, are of particular interest. Pair-wise interactions of a community of basidiomycetes were made under 3 different microclimate conditions that mimic fluctuations in local climate conditions, and the outcome of interactions was assessed in terms of: (1) which fungus won the confrontation or whether it was a draw (deadlock); (2) the production of volatile organic compounds (VOCs) and enzyme activities; and (3) the rate of decomposition. While substrate utilisation and exploitation in terms of decomposition was not affected, community response to changing temperature was underpinned by altered outcomes of interactions and changes to territory occupation, which were reflected by changes in VOC production and extracellular enzyme activity. This study underlines the importance of understanding the impact of community structure on carbon cycling in forest ecosystems under a changing climate

A population-based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection

Evidence on associations between COVID-19 vaccination or SARS-CoV-2 infection and the risk of congenital anomalies is limited. Here we report a national, population-based, matched cohort study using linked electronic health records from Scotland (May 2020-April 2022) to estimate the association between COVID-19 vaccination and, separately, SARS-CoV-2 infection between six weeks pre-conception and 19 weeks and six days gestation and the risk of [1] any major congenital anomaly and [2] any non-genetic major congenital anomaly. Mothers vaccinated in this pregnancy exposure period mostly received an mRNA vaccine (73.7% Pfizer-BioNTech BNT162b2 and 7.9% Moderna mRNA-1273). Of the 6731 babies whose mothers were vaccinated in the pregnancy exposure period, 153 had any anomaly and 120 had a non-genetic anomaly. Primary analyses find no association between any vaccination and any anomaly (adjusted Odds Ratio [aOR] = 1.01, 95% Confidence Interval [CI] = 0.83-1.24) or non-genetic anomalies (aOR = 1.00, 95% CI = 0.81-1.22). Primary analyses also find no association between SARS-CoV-2 infection and any anomaly (aOR = 1.02, 95% CI = 0.66-1.60) or non-genetic anomalies (aOR = 0.94, 95% CI = 0.57-1.54). Findings are robust to sensitivity analyses. These data provide reassurance on the safety of vaccination, in particular mRNA vaccines, just before or in early pregnancy

A population-based matched cohort study of early pregnancy outcomes following COVID-19 vaccination and SARS-CoV-2 infection

Our thanks to the EAVE II Patient Advisory Group and Sands charity for their support. COPS is a sub-study of EAVE II, which is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE—The Health Data Research Hub for Respiratory Health [MC_PC_19004], which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and Scottish Government DG Health and Social Care and the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation. COPS has received additional funding from Tommy’s charity. S.J.S. is funded by a Wellcome Trust Clinical Career Development Fellowship (209560/Z/17/Z). S.V.K. acknowledges funding from an NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17). K.B. is funded by a Wellcome Senior Research Fellowship (220283/Z/20/Z).Peer reviewedPublisher PD

A population-based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection.

Evidence on associations between COVID-19 vaccination or SARS-CoV-2 infection and the risk of congenital anomalies is limited. Here we report a national, population-based, matched cohort study using linked electronic health records from Scotland (May 2020-April 2022) to estimate the association between COVID-19 vaccination and, separately, SARS-CoV-2 infection between six weeks pre-conception and 19 weeks and six days gestation and the risk of [1] any major congenital anomaly and [2] any non-genetic major congenital anomaly. Mothers vaccinated in this pregnancy exposure period mostly received an mRNA vaccine (73.7% Pfizer-BioNTech BNT162b2 and 7.9% Moderna mRNA-1273). Of the 6731 babies whose mothers were vaccinated in the pregnancy exposure period, 153 had any anomaly and 120 had a non-genetic anomaly. Primary analyses find no association between any vaccination and any anomaly (adjusted Odds Ratio [aOR] = 1.01, 95% Confidence Interval [CI] = 0.83-1.24) or non-genetic anomalies (aOR = 1.00, 95% CI = 0.81-1.22). Primary analyses also find no association between SARS-CoV-2 infection and any anomaly (aOR = 1.02, 95% CI = 0.66-1.60) or non-genetic anomalies (aOR = 0.94, 95% CI = 0.57-1.54). Findings are robust to sensitivity analyses. These data provide reassurance on the safety of vaccination, in particular mRNA vaccines, just before or in early pregnancy